Long Term Development Agreement to Produce Reference Standard Reagents to
Advance Cancer Research
NEWARK, Del., April 3, 2008 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) -- a leader in providing advanced antibody products and services to the life sciences industry announced that it has been selected by Science Applications International Corporation - Frederick (SAIC-F), to develop monoclonal antibodies for the Proteomics Reagents & Resources component of the National Cancer Institute (NCI) Clinical Proteomic Technologies for Cancer initiative (CPTC). The goal of CPTC is to accelerate discovery and clinical research in cancer using an integrated approach that assesses and optimizes proteomic technology measurement capabilities and develops universally accepted metrics that identify and minimize experimental variability from run to run, instrument to instrument, and lab to lab. CPTC aims to achieve this through the optimization of existing platforms; developing innovative proteomic technologies and computational tools; and developing community reagents and resources. The Proteomic Reagents & Resources component will include SOPs, data, proteins, and well-characterized, high-quality antibodies whose performance characteristics will be conducted at an Antibody Characterization Laboratory at NCI-Frederick (NCI-F) that is part of NCI-F's Advanced Technology Program.
SDI was awarded the competitive contract to produce monoclonal antibodies that will serve as reference reagents for the scientific cancer community based on its technical strength, large-scale capacity, standardized processes, and fully integrated quality management system.
Matthew H. Knight, SDI's President and C
|SOURCE Strategic Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved